These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25998031)

  • 1. Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?
    Matsui K; Kamijo-Ikemori A; Sugaya T; Ikeda H; Okuse C; Shibagaki Y; Yasuda T; Kimura K
    Nephrology (Carlton); 2015 Nov; 20(11):843-8. PubMed ID: 25998031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
    Morihara D; Watanabe H; Takata K; Iwashita H; Tsuchiya N; Kunimoto H; Kuno S; Fukunaga A; Yotsumoto K; Tanaka T; Sakurai K; Hirano G; Yokoyama K; Nishizawa S; Yoshikane M; Anan A; Takeyama Y; Kitamura Y; Iwata K; Irie M; Shakado S; Sohda T; Sakisaka S
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):55-64. PubMed ID: 25370853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?
    Rémy AJ; Lesgourgues B; Nalet B; Causse X; Henrion J; Denis J; Arotçarena R; Hagège H; Pariente A;
    Eur J Gastroenterol Hepatol; 2014 Sep; 26(9):996-1002. PubMed ID: 25072384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
    Cotte L; Barrail-Tran A; Vincent C; Valantin MA; Fournier I; Lacombe K; Chevaliez S; Aboulker JP; Taburet AM; Molina JM;
    Antivir Ther; 2015; 20(5):479-86. PubMed ID: 25560644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.
    Karino T; Ozeki I; Hige S; Kimura M; Arakawa T; Nakajima T; Kuwata Y; Sato T; Ohmura T; Toyota J
    J Viral Hepat; 2014 May; 21(5):341-7. PubMed ID: 24001168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
    Milazzo L; Peri AM; Mazzali C; Magni C; Calvi E; De Nicolò A; Clementi E; Cheli S; D'Avolio A; Antinori S; Falvella FS
    J Antimicrob Chemother; 2015 Apr; 70(4):1155-60. PubMed ID: 25583751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection.
    Ogawa E; Furusyo N; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Nakamuta M; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    Antiviral Res; 2014 Apr; 104():102-9. PubMed ID: 24462955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discrepancy between serum creatinine and cystatin C can predict renal function after treatment for postrenal acute kidney injury: multicenter study and pooled data analysis.
    Matsuki M; Tanaka T; Maehana T; Kyoda Y; Ichihara K; Hashimoto K; Yanase M; Matsukawa M; Adachi H; Takahashi S; Masumori N
    Clin Exp Nephrol; 2017 Oct; 21(5):852-857. PubMed ID: 28258496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.
    Werner CR; Franz C; Egetemeyr DP; Janke-Maier P; Malek NP; Lauer UM; Berg CP
    J Viral Hepat; 2014 May; 21(5):333-40. PubMed ID: 24716636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.
    Gutierrez-Valencia A; Ruiz-Valderas R; Ben-Marzouk-Hidalgo OJ; Torres-Cornejo A; Espinosa N; Castillo-Ferrando JR; Viciana P; Lopez-Cortes LF
    Antimicrob Agents Chemother; 2015; 59(6):3257-62. PubMed ID: 25801562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
    Kozielewicz D; Dybowska D; Karwowska K; Wietlicka-Piszcz M
    Expert Opin Drug Saf; 2015; 14(12):1815-25. PubMed ID: 26513231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.
    De Nicolò A; Boglione L; Ciancio A; Cusato J; Strona S; Cardellino CS; Abdi AM; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Sep; 109():7-14. PubMed ID: 24956496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients.
    Van den Eynde E; Curto J; Ferrer E; Imaz A; Saumoy M; Di Yacovo S; Vila A; Podzamczer D
    AIDS; 2015 May; 29(8):977-9. PubMed ID: 25784438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.
    Atsukawa M; Tsubota A; Shimada N; Kondo C; Itokawa N; Nakagawa A; Fukuda T; Matsushita Y; Narahara Y; Osada Y; Yamaguchi H; Nakatsuka K; Iwakiri K; Kawamoto C; Sakamoto C
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):781-7. PubMed ID: 24732752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection.
    Kawano A; Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Dohmen K; Nomura H; Takahashi K; Satoh T; Azuma K; Tanabe Y; Shimoda S; Kotoh K; Hayashi J;
    Intern Med; 2015; 54(6):567-72. PubMed ID: 25790806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
    Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
    J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.